🔗 Share this article The Global Health Body Issues Alert Over Critical Lack of Obesity Jabs Under a tenth of people that would benefit from GLP-1 drugs such as Wegovy can access them, warns the World Health Organization as it publishes its inaugural advice on the drugs. With in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for increased and just availability to this class of drugs. Per estimates, over two billion are projected to be living with obesity by 2030 if no action is taken. "The new guidance acknowledges that excess weight is a long-term condition that can be addressed with comprehensive and ongoing support," stated its chief Tedros Adhanom Ghebreyesus. High costs, insufficient output, and supply-chain constraints are major hurdles to universal availability to the treatments that can aid individuals in losing significant weight, explains the organization. GLP-1 Therapy Shortage Even under the present most favorable scenario, the production of GLP-1 therapies could only cover around 100 million people – fewer than 10% of eligible patients, according to the health organization. The guideline encourages governments and firms to widen availability, via approaches such as licensing agreements. A patent on the active ingredient – the primary ingredient of Novo Nordisk's Wegovy – is set to lapse in several countries in 2026. How Obesity Injections Function The injections replicate a body's own hormone to slow digestion, reduce hunger and increase the sense of being full so individuals reduce food intake. Patients usually see weight reduction after several weeks of starting on the weekly injections. Research indicates people may put most of the weight back on within a year of halting the medication, when their usual food cravings return. To be above a healthy weight elevates your risk for developing health problems, such as diabetes, heart disease, brain attack, and some malignancies. Excess weight affects individuals in all nations and was linked to over three and a half million deaths worldwide in 2024, according to the WHO.
Under a tenth of people that would benefit from GLP-1 drugs such as Wegovy can access them, warns the World Health Organization as it publishes its inaugural advice on the drugs. With in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for increased and just availability to this class of drugs. Per estimates, over two billion are projected to be living with obesity by 2030 if no action is taken. "The new guidance acknowledges that excess weight is a long-term condition that can be addressed with comprehensive and ongoing support," stated its chief Tedros Adhanom Ghebreyesus. High costs, insufficient output, and supply-chain constraints are major hurdles to universal availability to the treatments that can aid individuals in losing significant weight, explains the organization. GLP-1 Therapy Shortage Even under the present most favorable scenario, the production of GLP-1 therapies could only cover around 100 million people – fewer than 10% of eligible patients, according to the health organization. The guideline encourages governments and firms to widen availability, via approaches such as licensing agreements. A patent on the active ingredient – the primary ingredient of Novo Nordisk's Wegovy – is set to lapse in several countries in 2026. How Obesity Injections Function The injections replicate a body's own hormone to slow digestion, reduce hunger and increase the sense of being full so individuals reduce food intake. Patients usually see weight reduction after several weeks of starting on the weekly injections. Research indicates people may put most of the weight back on within a year of halting the medication, when their usual food cravings return. To be above a healthy weight elevates your risk for developing health problems, such as diabetes, heart disease, brain attack, and some malignancies. Excess weight affects individuals in all nations and was linked to over three and a half million deaths worldwide in 2024, according to the WHO.